Shares in many large drugmakers fell Wednesday on the president's threat, which could further challenge an already battered ...

We recently published a list of 10 Defensive Stocks Billionaire Ken Fisher is Betting On. In this article, we are going to ...

Eli Lilly is reaping the benefits from its innovation in diabetes and obesity management, with therapies like Mounjaro and Zepbound generating billions of dollars in annual sales. The company has ...

To that end, let's consider five excellent growth-oriented companies to invest in on the dip: Novo Nordisk ( NVO -1.69%), Eli ...

"We’re going to tariff our pharmaceuticals, and once we do that, they’re going to come rushing back into our country because ...

Former top legal executives at large companies including Microsoft, Intel and Eli Lilly submitted a legal brief on Tuesday ...

Fintel reports that on April 8, 2025, Goldman Sachs upgraded their outlook for Eli Lilly and (NYSE:LLY) from Neutral to Buy.

UVA professor Dr. Christopher Kramer explains how a new Eli Lilly drug may cut a significant heart attack risk factor by 95%.

Across Wall Street, 44 publicly traded companies were upgraded Tuesday to an equivalent rating of "buy" or "neutral." ...

Eli Lilly (LLY) stock gains as Goldman Sachs upgrades it to Buy from Neutral citing the company's leadership position in the ...

Goldman Sachs upgraded Eli Lilly (LLY) to Buy from Neutral with a price target of $888, down from $892, after assuming coverage of the name.

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...